NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Consensus "Hold": Fourteen analysts have a consensus rating of Hold on NeoGenomics (1 sell, 8 hold, 5 buy) with an average 12‑month price target of about $11.86.
• Insider and institutional ownership: COO Warren Stone sold 22,128 shares at $12.50 (a 15.39% reduction in his position), insiders own ~2.4% of the stock while hedge funds and other institutions own ~98.5%.
• Quarterly results mixed: NeoGenomics beat EPS and revenue expectations (EPS $0.06 vs $0.04; revenue $190.17M, up 10.6% YoY) but remains unprofitable (negative net margin and ROE) and analysts forecast roughly -0.2 EPS for the current year.

NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) has earned a consensus rating of "Hold" from the fourteen analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $11.8571.

Several research firms recently weighed in on NEO. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NeoGenomics in a research note on Friday, March 27th. Piper Sandler raised their target price on shares of NeoGenomics from $12.00 to $13.00 and gave the company an "overweight" rating in a research note on Tuesday, February 24th. William Blair reaffirmed a "market perform" rating on shares of NeoGenomics in a research note on Monday, March 16th. UBS Group reaffirmed a "hold" rating on shares of NeoGenomics in a research note on Wednesday, February 18th. Finally, Benchmark reissued a "hold" rating on shares of NeoGenomics in a research note on Wednesday, February 18th.

Insider Activity at NeoGenomics

In related news, COO Warren Stone sold 22,128 shares of NeoGenomics stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total transaction of $276,600.00. Following the completion of the transaction, the chief operating officer directly owned 121,631 shares of the company's stock, valued at approximately $1,520,387.50. The trade was a 15.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.40% of the stock is owned by insiders.

Hedge Funds Weigh In On NeoGenomics

Large investors have recently made changes to their positions in the company. Aberdeen Group plc boosted its stake in shares of NeoGenomics by 91.8% during the 3rd quarter. Aberdeen Group plc now owns 792,263 shares of the medical research company's stock worth $6,116,000 after purchasing an additional 379,165 shares during the period. Squarepoint Ops LLC boosted its stake in shares of NeoGenomics by 246.8% during the 2nd quarter. Squarepoint Ops LLC now owns 735,473 shares of the medical research company's stock worth $5,376,000 after purchasing an additional 523,407 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of NeoGenomics during the 3rd quarter worth about $1,281,000. Greenhouse Funds LLLP boosted its stake in shares of NeoGenomics by 10.6% during the 3rd quarter. Greenhouse Funds LLLP now owns 8,220,657 shares of the medical research company's stock worth $63,463,000 after purchasing an additional 789,510 shares during the period. Finally, Silverback Asset Management LLC purchased a new position in shares of NeoGenomics during the 3rd quarter worth about $1,554,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

NeoGenomics Stock Up 4.0%

NEO opened at $8.00 on Tuesday. The company has a current ratio of 4.26, a quick ratio of 3.94 and a debt-to-equity ratio of 0.41. NeoGenomics has a 1-year low of $4.72 and a 1-year high of $13.74. The company has a market capitalization of $1.04 billion, a PE ratio of -9.52 and a beta of 1.72. The firm's 50 day simple moving average is $9.20 and its two-hundred day simple moving average is $10.48.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings results on Tuesday, February 17th. The medical research company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. NeoGenomics had a negative net margin of 14.85% and a negative return on equity of 3.10%. The business had revenue of $190.17 million for the quarter, compared to the consensus estimate of $188.25 million. During the same period last year, the firm earned $0.04 earnings per share. The company's quarterly revenue was up 10.6% on a year-over-year basis. As a group, equities analysts forecast that NeoGenomics will post -0.2 EPS for the current year.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company's core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.